The short version of freeze-dried powder fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-11 and is reviewed periodically as new material appears.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
| Property | Value | Notes |
|---|---|---|
| Name type | Commercial trade name | Not a systematic chemical identifier |
| Parent peptide | Thymosin beta-4 | 43-residue natural peptide |
| Common fragment sequence | LKKTETQ | Maps to part of the actin-binding region |
| Molecular size class | Roughly 0.8-1.0 kDa | Depends on exact fragment and terminal modification |
| Regulatory status | Prohibited in sport | Grouped with peptide hormones in many frameworks |
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Glutathione peroxidase 1, also known as GPx1, is an enzyme that in humans is encoded by the GPX1 gene on chromosome 3. This gene encodes a member of the glutathione peroxidase family. Glutathione peroxidase functions in the detoxification of hydrogen peroxide, and is one of the most important antioxidant enzymes in humans.
Early skin whitening practices were not well-documented. Skin whitening is a practice that has made its way across the entire globe with a multitude of cultures adopting the practice under various ideologies. Commonly, the practice has been marketed towards women under the pretense that porcelain skin was the ideal representation of beauty and status. The first recorded practices of skin whitening can be traced back to over 200 B.C. across a multitude of civilizations that utilized natural sources of ingredients to facilitate the production of skin whitening substances. One of these methods include the use of honey and olive oil as a method of whitening the skin in different civilizations such as in Egypt as well as in Greek culture. According to anthropologist Nina Jablonski, these practices did not become publicized until famous figures, such as Cleopatra and Queen Elizabeth, began to use them regularly. Cosmetic formulas initially spread from continental Europe and China to Britain and Japan, respectively. Various historians argue that, across cultures, skin lightening became a desirable norm due to implications of wealth. Although the majority methods of which the skin whitening process is undertaken have been deemed unsafe due to various side effects, they are still used for a range of purposes, including the desire for improvement of one's socioeconomic status as well as the socialization in some cultures of one's perceived inferiority based on having darker or lighter skin than others.
Mitral stenosis is uncommon and not as age-dependent as other types of valvular disease. Mitral insufficiency can be caused by dilation of the left heart, often a consequence of heart failure. In these cases, the left ventricle of the heart becomes enlarged and causes displacement of the attached papillary muscles, which control the mitral.
Sophia Hober (born 1965) is a Swedish researcher in biotechnology and professor at The Royal Institute of Technology (KTH) in Stockholm. Sophia Hober got her Master of Science in chemical engineering at KTH in 1989 and defended her doctorate in biochemistry in 1996. Since 2007, Hober is a professor of molecular biotechnology at KTH. During 2011–2015, Professor Hober served as dean at KTH and was part of the management team. Sophia Hober was elected member of the Royal Swedish Academy of Engineering Sciences in 2012. Hober's research is centered around the development of affinity proteins for use in biotechnology and medicine. Her main scientific achievements in the field of protein purification include improvements of the alkaline tolerance of protein A for the industrial purification of monoclonal antibodies. This work led to the product MabSelect SuRe, currently sold by Cytiva. Professor Hober has also developed a new protein domain with calcium-dependent affinity that can be used for gentle purification of monoclonal antibodies. Further in her work she has developed protein domains with the ability to strongly and selectively bind cancer markers. One of these has, in clinical trials, been shown to work very well for the precision diagnosis of cancer in situ. Hober is, among others, a co-founder of the biotechnology companies Affibody AB and Atlas Antibodies AB.
Sources: en.wikipedia.org
The deportees were released on 19 December and allowed to travel to Cairo and then, with Jamal Husseini, to Beirut where a new Arab Higher Committee (or Higher National Committee) was established. Amin al-Husayni was not a member of the Arab delegation but the delegation was clearly acting under his direction. The London Conference commenced on 7 February 1939, but the Arab delegation refused to sit in the same room with the Jewish delegation present, and the conference broke up in March with no success. In May 1939, the British government presented its 1939 White Paper which was rejected by both sides. The White Paper had, in effect, repudiated the Balfour Declaration. According to Benny Morris, Amin al-Husayni "astonished" the other members of the Arab Higher Committee by turning down the White Paper. Al-Husayni turned the advantageous proposal down because "it did not place him at the helm of the future Palestinian state." The deportees were not allowed to return to Palestine until 1941. Amin Al-Husayni spent the war years in occupied Europe, actively collaborating with the Nazi leadership. Amin and Jamal al-Husayni were involved in the 1941 pro-Nazi Rashidi revolt in Iraq. Amin again evaded capture by Britain but Jamal was captured in 1941 and interned in Southern Rhodesia, where he was held until November 1945 when he was allowed to move to Cairo. Husayn al-Khalidi returned to Palestine in 1943. Jamal al-Husayni returned to British Palestine in February 1946 as an official of the new Arab Higher Committee, by then recognised by the Mandate administration.
=== Thioredoxin reductase === Thioredoxin reductase uses a cysteine-selenocysteine pair to reduce the disulfide in thioredoxin. The selenocysteine is arranged in an unusual Sec-His-Glu catalytic triad, which tunes its pKa.
=== Synthesis === The cyclic dipeptide Epelsiban is formed by cyclizing the corresponding linear dipeptide. In the highly stereoselective synthesis of Epelsiban 11, the linear peptide 8 is formed by the four-component Ugi reaction of the carboxybenzyl (Cbz) protected R-indanylglycine 4, D-alloisoleucine methyl ester hydrochloride 5, 2,6-dimethylpyridine-3-carboxaldehyde 6 and 2-benzyloxyphenylisonitrile 7. Hydrogenation to remove the Cbz and benzyl protecting groups, enabled cyclization of the linear peptide 8 to occur to give the phenolic cyclic dipeptide 9. Hydrolysis of the phenolic amide, by reaction with carbonyl diimidazole (CDI), followed by the addition of aqueous hydrochloric acid gave the acid 10 which was converted to the amide Epelsiban 11 by activating the acid with the peptide coupling reagent CDI, followed by the addition of morpholine. In this short lab-scale synthesis although the linear peptide 8 and the cyclic dipeptide 9 are a mixture of diastereoisomers (7RS) at the exocyclic amide, the hydrochloric acid hydrolysis of the activated phenolic amide caused epimerisation at the exocyclic position and yielded the acid 10 with the required (7R)-stereochemistry as the major product.
== Causes == While the mechanism of the disease has yet to be fully elucidated, the leading hypothesis is that AAV (ANCA Associated Vasculitis) develops in patients with a genetic predisposition when an unknown cause triggers the production of p-ANCA. These antibodies will circulate at low levels until an environmental trigger—such as infection, malignancy, or drug therapy, causes the upregulation of neutrophils. The neutrophils bind to p-ANCAs and subsequently release inflammatory cytokines, reactive oxygen species and lytic enzymes that cause endothelial injury resulting to inflammation and necrosis of the small vessels. The damage that is caused in the kidneys is specifically called necrotizing and crescentic glomerulonephritis.
Regarding the death of Henry King, Jr., Johns revealed that he always "had a finite story", going "from this almost unlikeable bully to possibly a redeemed hero, and then ultimately die protecting his new friends when facing his father, while also learning a lesson that Courtney imparted on him and apologizing to Yolanda". Johns spoke with actor Jake Austin Walker before he signed on to play the character to inform him of this and discuss the character with him. The character's return in the season one finale with his father pretending to be his son was done to subvert the "nobody ever dies" superhero trope. Yolanda Montez's struggle with killing Brainwave was "a big part of season 2". Johns added that compared to Rick Tyler, who is "starting to kind of turn a corner" after overcoming his anger for his parents' death, Yolanda is "turning the other way... She's lost in her own world, thinking about what she has done" since she was not ready to kill someone, unlike Rick. Additionally, more motivations from the surviving members of the Injustice Society are explored in the second season. Bassinger teased that the third season would feature a murder mystery.
Sources: en.wikipedia.org
In response to declining sales, in 2017 the company launched a fast casual spinoff of its format called "Hoots". Hoots is distinguished from its original concept primarily by a reduction in menu items and employment of both male and female servers who are modestly dressed in t-shirts and khakis.
== List of virucides == Note that many of the substances, if sold commercially, are usually combinations and mixtures with varying molecular contents. Also note that most products have a limited viricide efficacy. A specific test-protocol is applied. The lists' scope is limited. For further products refer to other lists. Other factors such as stability of the concentrate, application concentration, exposure time, timing of the solution, hydrogen ion concentration (pH value), temperature, etc. play an certain role for the effectivity of a virucide. EPA is providing a public listing called "List N"
== Reaction from sports organizations == Many sports organizations have banned the use of performance-enhancing drugs and have very strict rules and penalties for people who are caught using them. The International Amateur Athletic Federation, now World Athletics, was the first international governing body of sport to take the situation seriously. In 1928 they banned participants from doping, but with little in the way of testing available they had to rely on the word of the athlete that they were clean. It was not until 1966 that FIFA and Union Cycliste Internationale (cycling) joined the IAAF in the fight against drugs, followed by the International Olympic Committee the following year. Progression in pharmacology has always outstripped the ability of sports federations to implement rigorous testing procedures but since the creation of the World Anti-Doping Agency in 1999, it has become more effective to catch athletes who use drugs. The first tests for athletes were at the 1966 European Championships and two years later the IOC implemented their first drug tests at both the Summer and Winter Olympics. Anabolic steroids became prevalent during the 1970s and after a method of detection was found they were added to the IOC's prohibited substances list in 1975, after which the 1976 Summer Olympics in Montreal were the first Olympic Games which tested for them. Over the years, different sporting bodies have evolved differently in the struggle against doping. Some, such as athletics and cycling, are becoming increasingly vigilant against doping.
Toronto City Council has announced its intention to challenge the bill on legal grounds. In July 2025, an Ontario court ruled that removing Toronto bike lanes was unconstitutional; the government will appeal the decision. In August 2026, the Ontario appeals court ruled that there is no constitutional obligation to regulate the use of roads in any particular manner, allowing Ford's government to remove Toronto bike lanes. In 2025, automated speed enforcement fell under controversy. The Kathleen Wynne Liberal government introduced legislation allowing automated speed enforcement in 2017, before the Ford government passed it in 2019. By October 2025, Ford announced legislation that would ban the use of speed cameras, calling them "cash grabs". The move came after many speed cameras in Toronto were vandalized. Over 20 mayors, including Olivia Chow of Toronto, spoke out against the proposed legislation, as well as municipalities, school boards, and police chiefs. On November 14, the Building a More Competitive Economy Act was passed, that struck the section of the Highway Traffic Act that permitted automated speed enforcement. Instead, the government launched a $210 million road safety initiatives fund for municipalities to implement traffic calming measures. His government has also reinstated the Northlander passenger train service and has broken ground on the East Harbour Transit Hub. Ford also expanded GO Transit services.
== Categorization == The Rho family of GTPases belong to the Ras superfamily of proteins, which consists of over 150 varieties in mammals. Rho proteins sometimes denote some members of the Rho family (RhoA, RhoB, and RhoC), and sometimes refers to all members of the family. This article is about the family as a whole. In mammals, the Rho family contains 20 members. Almost all research involves the three most common members of the Rho family: Cdc42, Rac1 and RhoA.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.
Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.
Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.